Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis

Fig. 2

IRF4 prognostic impact in Ph-MPNs. A LFS analysis in all MPN patients included in this study according to the IRF4 expression value. B LFS analysis in MF patients according to the IRF4 expression value. C LFS analysis in PMF patients according to the IRF4 expression value. D OS analysis in MF patients according to the IRF4 expression value. E OS analysis in PMF patients according to the IRF4 expression value. F Probability analysis of evolution to post-PV and post-ET MF according to the IRF4 expression value. The cut off of the IRF4 expression (0.022) was calculated by ROC analysis

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us